Loading data for RXRX — first visit, this takes a few seconds.
Recursion Pharmaceuticals, Inc. (RXRX)
NasdaqGS: RXRX
· Real-Time Price · USD
3.40
+0.06 (1.80%)
At close: Sep 04, 2026, 8:00 PM
3.64
+0.28%
After-hours: 7:59 PM
The price, the headline numbers and the latest news, in one place.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, Analysis & Data
No data available
| Bid | 3.39 |
| Market Cap | 1.95B |
| Revenue (ttm) | 54.9M |
| Net Income (ttm) | -519M |
| 1.07 | |
| -1 | |
| n/a | |
| -4.06 | |
| P/B (ttm) | 2.12 |
| P/S (ttm) | 35.49 |
| Earnings Date | Nov 4, 2026 |
| Ask | 3.4 |
| Volume | 13,891,977 |
| Avg. Volume (20D) | 20,120,641 |
| Open | 3.30 |
| Previous Close | 3.34 |
| Day's Range | 3.25 - 3.40 |
| 52-Week Range | 2.77 - 7.18 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RXRX
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 cli...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 16, 2021
Employees 600
Stock Exchange NasdaqGS
Ticker Symbol RXRX
Website https://www.recursion.com
Financial Performance
In 2025, Recursion Pharmaceuticals's revenue was 74.26M, an increase of 26.96% compared to the previous year's 58.49M. Earnings were -644.76M, an increase of 39.06%.
Financial StatementsEarnings Surprise
Recursion Pharmaceuticals has released their quarterly earnings on Aug 5, 2026:
- Revenue of $7.3M misses estimates by $0, with -61.77% YoY decline.
- EPS of -0.25 misses estimates by -0.02, with 39.02% YoY growth.
Recursion Pharmaceuticals, Inc. is scheduled to release its earnings on Nov 4, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2